Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trimodulin (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Acronyms CIGMA
- Sponsors Biotest AG
- 03 Apr 2020 According to a Biotest AG media release, Very good results have already been achieved in a large-scale Phase II study in mechanically ventilated patients with severe pneumonia (severe Community Acquired Pneumonia = sCAP) (CIGMA study). This group of diseases also includes pneumonia caused by the current coronavirus in critically ill patients.
- 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2015 Planned End Date changed from 1 May 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.